Although an initial response to levodopa may occur, patients often lose this response.31 FTDP-17 may exhibit clinical signs of PSP, CBD, and AD.31 FTDP-17 presents with tau aggregates as a result of a mutation in the MAPT gene on chromosome 17.30, 31. The gene discussed is MAPT; the disease is red-green color blindness.